2023-08-09 08:14:47 ET
- Agile Therapeutics press release ( NASDAQ: AGRX ): Q2 Non-GAAP EPS of -$3.10 beats by $1.85 .
- Revenue of $5.5M (+158.2% Y/Y) beats by $0.87M .
- Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to First Quarter 2023
- Gross Margin Grows to 58% in Second Quarter 2023 from 47% in First Quarter 2023
- Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million
- Shares +4.64% PM.
For further details see:
Agile Therapeutics Non-GAAP EPS of -$3.10 beats by $1.85, revenue of $5.5M beats by $0.87M